Senzar Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Senzar Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-506,900	Closed	-$13.5M	–	32
2016 Q3	$13.5M	Buy	506,900 +24,900	+5%	+$578K	3.49%	8
2016 Q2	$10.6M	Buy	482,000 +143,149	+42%	+$3.75M	2.32%	13
2016 Q1	$9.95M	Buy	338,851 +174,865	+107%	+$4.87M	1.98%	18
2015 Q4	$5.41M	Buy	+163,986	New	+$5.34M	0.6%	31
2015 Q2	–	Sell	-154,300	Closed	-$4.72M	–	40
2015 Q1	$4.72M	Buy	154,300 +110,183	+250%	+$4.29M	1.15%	24
2014 Q4	$2.24M	Sell	44,117 -522,786	-92%	-$23.4M	0.66%	32
2014 Q3	$22.4M	Buy	566,903 +311,775	+122%	+$12.4M	6.58%	7
2014 Q2	$11M	Buy	255,128 +114,000	+81%	+$4.35M	4.2%	10
2014 Q1	$5.64M	Sell	141,128 -19,343	-12%	-$703K	2.99%	12
2013 Q4	$4.38M	Buy	+160,471	New	+$3.89M	3.58%	13

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Senzar Asset Management's ENTA Position: Q4 2016 in Review

Senzar Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2016, closing a stake of 506,900 shares — an estimated $13.5M sold.

Senzar Asset Management first reported a position in ENTA in Q4 2013 and held it in 10 quarters. The position peaked at $22.4M in Q3 2014. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

Senzar Asset Management reported no remaining Enanta Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Senzar Asset Management sold 506,900 Enanta Pharmaceuticals shares in Q4 2016, an estimated $13.5M.
Senzar Asset Management first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Senzar Asset Management's Enanta Pharmaceuticals position peaked at $22.4M in Q3 2014.
149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on Senzar Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.